Instructions for use of ALVESCO® (ALVESCO®)
The drug should be used with caution in patients with active or chronic pulmonary tuberculosis; in patients with bacterial, viral or fungal infections of the respiratory tract.
Alvesco® is not indicated for the treatment of status asthmaticus or other acute attacks of bronchial asthma requiring intensive therapeutic measures.
Alvesco® is not intended for the relief of symptoms of exacerbation of bronchial asthma, which requires the use of short-acting inhaled bronchodilators. Patients should be advised to carry such medications with them at all times.
Patients with severe bronchial asthma are at risk of having an attack of suffocation. Such patients should undergo regular examination to confirm the adequacy of treatment, including pulmonary function testing. The increasing use of short-acting bronchodilators to relieve asthma symptoms indicates that treatment is inadequate. If the patient feels that the effect of short-acting bronchodilators is weakening or an increase in the frequency of inhalations is noted, the patient's condition should be re-evaluated and, if necessary, the dose of Alvesco® should be increased or parenteral corticosteroids should be prescribed. Treatment for severe exacerbations of asthma is usual.
Inhaled corticosteroids may cause systemic effects, especially when used in high doses for long periods of time. However, systemic effects are more likely to occur with oral corticosteroids. Possible systemic effects include Cushing's syndrome and Cushing-like symptoms such as adrenal suppression with hypoglycemic episodes, growth retardation in children and adolescents, decreased bone density, cataracts, and glaucoma. This is why it is important that the dose of inhaled corticosteroid is reduced to the lowest dose that provides satisfactory control of the disease.
The use of Alvesco® should be accompanied by a reduction in the need for parenteral corticosteroids.
For patients transferred from oral corticosteroid therapy to inhaled treatment with Alvesco®, the risk of decreased adrenal function may remain for a significant period of time after the transfer. The possibility of developing undesirable effects from the use of oral corticosteroids may persist for some time after their discontinuation. In such cases, before treatment, it is recommended to conduct a special study to determine the degree of decrease in adrenal function. The possibility of residual deterioration of adrenal function in critical situations (therapeutic or surgical) and in other individual cases that may be caused by a stress reaction should always be taken into account; therefore, appropriate treatment with corticosteroids should be initiated.
In case of insufficient therapeutic response or serious exacerbations, the dose of Alvesco® should be increased; if necessary, oral corticosteroids should be used.
If infection develops, antibiotics should be used.
Treatment with Alvesco® should not be abruptly stopped.
Paradoxical bronchospasm with increased wheezing and other symptoms of bronchoconstriction that appear immediately after inhalation should be treated with a fast-acting bronchodilator, which usually leads to rapid relief. The patient should be examined and therapy with Alvesco® continued only if, after careful consideration, the expected benefit is higher than the possible risk. The relationship between the severity of asthma and the general susceptibility to acute bronchial reactions should be taken into account.
Patients' inhalation technique should be regularly monitored to ensure that the inhalation dose is taken correctly and that the delivery of the active substance to the lungs is optimal.
Transfer of patients taking oral corticosteroids to Alvesco®
When transferring to Alvesco® and subsequent management of patients treated with oral corticosteroids, physician supervision is required, because restoration of reduced adrenal function caused by prolonged systematic therapy with corticosteroids may take some time.
Patients receiving systemic corticosteroids for a long time or at high doses may experience suppression of adrenal function. Adrenal function in these patients should be monitored regularly, and the dose of systemic corticosteroids should be reduced gradually.
After approximately one week, gradual elimination of systemic corticosteroids can be started, reducing their daily dose by 1 mg of prednisolone, or its equivalent. For maintenance dosages of prednisolone greater than 10 mg daily, greater dose reductions over weekly intervals may be appropriate, but caution is warranted.
Some patients may feel unwell during drug withdrawal, despite maintaining or even improving respiratory function. They should be examined for the presence of adrenocortical insufficiency.
Patients transitioned from oral corticosteroids and whose adrenal function is still compromised should be provided with a warning card indicating that they require additional systemic corticosteroids during periods of stress (eg, worsening asthma attacks, thoracic infections, significant intercurrent illnesses, surgical interventions, injuries, etc.).
When transferring patients from taking systemic corticosteroids to inhalation therapy, allergic reactions (for example, allergic rhinitis, eczema), which were previously suppressed by systemic drugs, may occur. In such cases, symptomatic therapy with antihistamines should be carried out, incl. preparations for external and local use containing GCS.
Use in pediatrics
Use of the drug in children under 6 years of age
contraindicated.
The effect of inhaled corticosteroids during long-term use in children has not been fully elucidated. The physician should constantly monitor the development of growth in children taking GCS for a long period. If growth slows down, then therapy should be reconsidered in order to reduce the dose of inhaled corticosteroids, if possible, to the minimum effective, which allows to control the symptoms of bronchial asthma.
Impact on the ability to drive vehicles and operate machinery
The effect of Alvesco® on the ability to drive vehicles and operate machinery has not been specifically studied and seems unlikely.
Alvesco®
Alvesco® is not indicated for the treatment of status asthmaticus or other acute attacks of bronchial asthma requiring intensive therapeutic measures.
The dose of Alvesco® may be reduced in patients requiring oral corticosteroids.
For patients transferred from oral corticosteroid therapy to inhaled treatment with Alvesco®, a decrease in adrenal function may persist for a significant period of time after the transfer. The possibility of developing undesirable effects from the use of oral corticosteroids may persist for some time after their discontinuation. In such cases, it is recommended to monitor the reserve function of the adrenal cortex. The possibility of residual deterioration of adrenal function in a critical situation (therapeutic or surgical) and in other individual cases that may be caused by a stress reaction should always be taken into account, and therefore appropriate treatment with corticosteroids should be initiated.
In case of insufficiency of adrenal cortex function or serious exacerbations, the dose of Alvesco® should be increased; if necessary, oral corticosteroids should be used.
If infection develops, antibiotics should be used.
Paradoxical bronchospasm with increased wheezing and other symptoms of bronchoconstriction that appear immediately after inhalation should be treated with a fast-acting bronchodilator, which usually leads to rapid relief. The patient should be examined and therapy with Alvesco® continued only if, after careful consideration, the expected benefit is higher than the possible risk. The relationship between the severity of asthma and the general susceptibility to acute bronchial reactions should be taken into account.
Transfer of patients taking oral corticosteroids to Alvesco®
When transferring to Alvesco® and subsequent management of patients treated with oral corticosteroids, physician supervision is required, because restoration of reduced adrenal function caused by prolonged systematic therapy with corticosteroids may take some time.
Patients receiving systemic corticosteroids for a long time or at high doses may experience suppression of adrenal function. The adrenal function of these patients should be monitored regularly, and the dose of systemic corticosteroids should be reduced gradually.
After approximately one week, gradual elimination of systemic corticosteroids can be started, reducing their daily dose by 1 mg of prednisolone, or its equivalent. For maintenance dosages of prednisolone greater than 10 mg daily, greater dose reductions over weekly intervals may be appropriate, but caution is warranted.
Some patients may feel unwell during drug withdrawal, despite maintaining or even improving respiratory function. They should be examined for the presence of adrenocortical insufficiency.
When transferring patients from taking systemic corticosteroids to inhalation therapy, allergic reactions (for example, allergic rhinitis, eczema), which were previously suppressed by systemic drugs, may occur. In such cases, symptomatic therapy with antihistamines should be carried out, incl. preparations for external and local use containing GCS.
Use in pediatrics
Use of the drug in children under 6 years of age
contraindicated.
The effect of inhaled corticosteroids during long-term use in children has not been fully elucidated. The physician should constantly monitor the development of growth in children taking GCS for a long period. If growth slows down, then therapy should be reconsidered in order to reduce the dose of inhaled corticosteroids, if possible, to the minimum effective, which allows to control the symptoms of bronchial asthma.
Impact on the ability to drive vehicles and operate machinery
There is no data on the effect of the drug on the ability to drive vehicles and machines.
Alvesco, 80 mcg/spray, dosed aerosol for inhalation, 5 ml, 1 pc.
Alvesco® is not indicated for the treatment of status asthmaticus or other acute episodes of asthma requiring intensive therapeutic measures.
The effect of inhaled corticosteroids during long-term use in children has not been fully elucidated. The doctor should constantly monitor the growth of children taking GCS for a long period. If growth slows down, therapy should be reconsidered in order to reduce the dose of inhaled corticosteroids. If possible, then to the lowest dose that maintains constant control of asthma symptoms. The dose of Alvesco® may be reduced in patients requiring oral corticosteroids.
For patients transferred from oral corticosteroid therapy to inhaled treatment with Alvesco®, a decrease in adrenal function may persist for a significant period of time after the transfer. The possibility of developing undesirable effects from the use of oral corticosteroids may persist for some time after their discontinuation. In such cases, it is recommended to monitor the reserve function of the adrenal cortex. The possibility of residual deterioration of the adrenocortical response in a critical situation (therapeutic or surgical) and in other individual cases that may be caused by a stress reaction should always be taken into account, as a result of which appropriate GCS treatment should be initiated.
In case of insufficient adrenocortical response or severe exacerbations, the dose of Alvesco® should be increased; if necessary, oral corticosteroids should be used. In case of infection, antibiotics should be used. Paradoxical bronchospasm with increased wheezing and other symptoms of bronchoconstriction that appear immediately after inhalation should be treated with a fast-acting bronchodilator, which usually leads to rapid relief. The patient should be assessed and therapy with Alvesco® should only be continued if, after careful consideration, the expected benefit is greater than the possible risk. The relationship between the severity of asthma and the general susceptibility to acute bronchial reactions should be taken into account.
Transfer of patients taking oral corticosteroids to Alvesco®.
The transfer of patients treated with oral corticosteroids to Alvesco® and their subsequent management requires attention, because restoration of reduced adrenal function caused by prolonged systematic corticosteroid therapy may take some time.
Patients taking systemic corticosteroids for a long period of time or at high doses may experience suppression of adrenal function. Adrenal function in these patients should be monitored regularly, and the dose of systemic corticosteroids should be reduced gradually. After approximately one week, gradual elimination of systemic corticosteroids can be started, reducing their daily dose by 1 mg of prednisolone or its equivalent. For maintenance doses of prednisolone above 10 mg daily, larger dose reductions over weekly intervals may be appropriate, cautiously undertaken.
Some patients may feel unwell during drug withdrawal, despite maintaining or even improving respiratory function. They should be evaluated for adrenocortical insufficiency.
When transferring patients from taking systemic corticosteroids to inhalation therapy, allergic reactions (for example, allergic rhinitis, eczema), which were previously suppressed by systemic drugs, may occur. These allergies should be treated symptomatically with antihistamines and/or topical agents, including topical corticosteroids.
Impact on the ability to drive a car or perform work that requires increased speed of physical and mental reactions.
There is no data on the effect of the drug on the ability to drive vehicles and machines.
Alvesco aerosol d/ing doses 160 µg/spray 60 DOZES 5 ml
special instructions
Alvesco® is not indicated for the treatment of status asthmaticus or other acute attacks of bronchial asthma requiring intensive therapeutic measures.
The dose of Alvesco® may be reduced in patients requiring oral corticosteroids. For patients transferred from oral corticosteroid therapy to inhaled treatment with Alvesco®, a decrease in adrenal function may persist for a significant period of time after the transfer. The possibility of developing undesirable effects from the use of oral corticosteroids may persist for some time after their discontinuation. In such cases, it is recommended to monitor the reserve function of the adrenal cortex. The possibility of residual deterioration of adrenal function in a critical situation (therapeutic or surgical) and in other individual cases that may be caused by a stress reaction should always be taken into account, and therefore appropriate treatment with corticosteroids should be initiated. In case of insufficiency of adrenal cortex function or serious exacerbations, the dose of Alvesco® should be increased; if necessary, oral corticosteroids should be used. If infection develops, antibiotics should be used. Paradoxical bronchospasm with increased wheezing and other symptoms of bronchoconstriction that appear immediately after inhalation should be treated with a fast-acting bronchodilator, which usually leads to rapid relief. The patient should be examined and therapy with Alvesco® continued only if, after careful consideration, the expected benefit is higher than the possible risk. The relationship between the severity of asthma and the general susceptibility to acute bronchial reactions should be taken into account. Transfer of patients taking oral corticosteroids to Alvesco® When transferring to Alvesco® and subsequent management of patients treated with oral corticosteroids, physician supervision is required, because restoration of reduced adrenal function caused by prolonged systematic therapy with corticosteroids may take some time. Patients receiving systemic corticosteroids for a long time or at high doses may experience suppression of adrenal function. The adrenal function of these patients should be monitored regularly, and the dose of systemic corticosteroids should be reduced gradually. After approximately one week, gradual elimination of systemic corticosteroids can be started, reducing their daily dose by 1 mg of prednisolone, or its equivalent. For maintenance dosages of prednisolone greater than 10 mg daily, greater dose reductions over weekly intervals may be appropriate, but caution is warranted. Some patients may feel unwell during drug withdrawal, despite maintaining or even improving respiratory function. They should be evaluated for the presence of adrenocortical insufficiency. When transferring patients from taking systemic corticosteroids to inhalation therapy, allergic reactions (for example, allergic rhinitis, eczema), which were previously suppressed by systemic drugs, may occur. In such cases, symptomatic therapy with antihistamines should be carried out, incl. preparations for external and local use containing GCS. Use in pediatrics The use of the drug in children under 6 years of age is contraindicated. The effect of inhaled corticosteroids during long-term use in children has not been fully elucidated. The physician should constantly monitor the development of growth in children taking GCS for a long period. If growth slows down, then therapy should be reconsidered in order to reduce the dose of inhaled corticosteroids, if possible, to the minimum effective, which allows to control the symptoms of bronchial asthma.
Essentialcaps is one of the effective medicines for treating the liver.
- Medicines
- Gastroenterology, Therapy
The liver is a unique organ of the human body. A few facts about the liver:
• It is the heaviest organ and can weigh up to one and a half kilograms. • The human liver filters up to two thousand liters of blood per day. • This organ is also the “hottest” - with significant cooling of the entire human body, the liver has the ability to warm the entire body. • With the help of the liver, ten (!) times more oxygen is burned than muscles of the same mass. • Already in the eighth week of development, the liver occupies half the weight of the entire embryo. • It is one of the few organs that can restore its original size from 1⁄4 of healthy tissue. • Every year, 11,000 liver transplants are performed worldwide, with 10,000 of these procedures performed in the United States and European countries. The ancient Chinese called the liver the “mother” of the whole body, because it is the main filter, it is she who takes all toxins, poisons, allergens and removes toxic products from the body. If it were not for this vital function of the liver, the person would simply die within a few hours. The liver also stores a supply of certain vitamins, such as vitamin A, B12, D and others. If there is a lack of these vitamins in food, the body makes up for their deficiency precisely thanks to reserves in the liver.
The liver also plays an important role in the functioning of the immune system. It is here that immunoglobulins and antibodies, amino acids, and proteins involved in maintaining the functioning of the immune system are produced. That’s why supporting your immune system needs to start with taking care of your liver! Frequent consumption of alcohol, an abundance of fatty foods, decreased physical activity, violation of the rules of taking medications, viral diseases - all these factors lead to damage to liver cells, and this can disrupt the functioning of the entire liver. However, the liver never hurts. Nature has deprived the liver tissue of pain receptors - a very important fact follows from this: this organ needs to be supported in moments of crisis for it (intoxication, alcohol intake, viral diseases) even without symptoms, when a person has neither pain in the right hypochondrium nor a feeling of discomfort .
To maintain liver function and treat its diseases, in addition to a healthy diet, avoiding alcohol and toxic substances, it is necessary to help liver cells maintain the integrity of cell membranes. And for this, the human body must receive the structural elements of these cells - essential phospholipids. The stronger the phospholipid layer in a liver cell, the longer the cell maintains its structural integrity and the normal functioning of the entire liver is maintained.
Liver treatment
The pharmaceutical company Minskintercaps produces the medicine Essencicaps. One capsule of Essentialcaps contains 300 mg of essential phospholipids. The raw materials for the production of this drug are produced and purchased in Germany. When taking the medicine Essencecapsa, phospholipids are embedded in the membranes of liver cells, replace damaged areas, and restore normal functioning of the entire liver. At the same time, the development of liver fibrosis is prevented, the antioxidant effect of phospholipids is manifested, and the characteristics of bile are improved. Essentialcaps is intended for the complex treatment of liver diseases: acute and chronic hepatitis, fatty liver disease (also for diabetes). Indications for taking Essencicaps are also toxic (drug, alcohol) damage to the liver. Take Essencicaps 2 capsules 2-3 times a day with meals. There are no restrictions on the duration of treatment. It is important to emphasize that the course of treatment is at least three months to completely saturate liver cell membranes with phospholipids. Remember that liver maintenance must occur in a timely manner, so after drinking alcohol, long-term use of medications (antibiotics, antifungal drugs, paracetamol, antitumor, hormonal, anti-inflammatory drugs, help your liver by taking Essencecaps! Take care of yourself and your liver!
